Take an in-depth look at the treatment procedure for XIAFLEX® with one of the country's well-established injectors of XIAFLEX®, Dr. Martin Gelbard.
Dr. Gelbard is a urologist with more than 30 years of experience in the study of Peyronie's disease. He has also served as the principal investigator in several studies, and had been involved with the 2 pivotal clinical trials for XIAFLEX®.
Learn about the pathologic wound healing that is characteristic of Peyronie's disease.
XIAFLEX® should only be administered by a doctor experienced in the treatment of male urological diseases who has completed required Risk Evaluation and Mitigation Strategy (REMS) training for use of XIAFLEX® in the treatment of Peyronie's disease.1
To learn more about becoming a trained injector of XIAFLEX®, visit www.XIAFLEXREMS.com or call 1-877-313-1235.
A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug and is required by the Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh the risks. Endo has worked with the FDA to develop the XIAFLEX® REMS Program.
Because of the risks of corporal rupture and other serious injuries to the penis in the treatment of Peyronie's disease, XIAFLEX® is available only through the XIAFLEX® REMS Program.
Help patients get the conversation started using the helpful questions in this discussion guide.
Educate patients starting out with XIAFLEX® on the 2 equally important parts of their treatment: working with a urologist and the important role patients play at home with penile modeling.